Atlantic Trust Group LLC lifted its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 32.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,171 shares of the medical equipment provider’s stock after buying an additional 6,860 shares during the quarter. Atlantic Trust Group LLC’s holdings in Zimmer Biomet were worth $3,298,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. increased its position in Zimmer Biomet by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 167 shares in the last quarter. Bank of Nova Scotia Trust Co. purchased a new stake in Zimmer Biomet in the 3rd quarter valued at about $112,000. FNY Managed Accounts LLC purchased a new stake in Zimmer Biomet in the 3rd quarter valued at about $117,000. Steward Partners Investment Advisory LLC purchased a new stake in Zimmer Biomet in the 3rd quarter valued at about $140,000. Finally, BB&T Investment Services Inc. purchased a new stake in Zimmer Biomet in the 2nd quarter valued at about $144,000. 85.92% of the stock is owned by institutional investors and hedge funds.
Several analysts have commented on ZBH shares. Deutsche Bank upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a report on Tuesday, November 14th. Edward Jones upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. SunTrust Banks set a $136.00 target price on Zimmer Biomet and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group reiterated a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. Finally, BMO Capital Markets reiterated a “buy” rating and set a $142.00 target price on shares of Zimmer Biomet in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $137.42.
Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $122.29 on Friday. The company has a market capitalization of $24,760.00, a price-to-earnings ratio of 38.10, a P/E/G ratio of 1.96 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet Holdings Inc has a 52 week low of $108.03 and a 52 week high of $133.49.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a return on equity of 3.82% and a net margin of 5.43%. Zimmer Biomet’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.79 earnings per share. analysts anticipate that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Stockholders of record on Friday, December 29th will be paid a $0.24 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet’s payout ratio is 29.91%.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/12/zimmer-biomet-holdings-inc-zbh-shares-bought-by-atlantic-trust-group-llc-2.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.